← Back to All Filings
Alnylam Pharmaceuticals CEO Yvonne Greenstreet Awarded 107 Shares for 10-Year Service Milestone
ALNYLAM PHARMACEUTICALS, INC.
$ALNY4CIK: 0001178670
Subscribe to track ALNY
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# SEC Form 4 Alert: ALNYLAM PHARMACEUTICALS, INC. ($ALNY)
**Insider:** Yvonne Greenstreet (Chief Executive Officer, Director)
**Transaction Date:** September 19, 2026
**Filing Date:** September 22, 2026
### Transaction Summary
- **Type:** Stock Grant / Award (Service Milestone)
- **Shares:** +107 shares
- **Price:** $0.00
- **Gross Value:** $0 ($50,000 policy grant value net of tax withholdings)
- **Direct Holdings Post-Transaction:** 95,802 shares
- **Indirect Holdings:** 407 shares (Managed Account / 401(k))
### Significance
**Low**: Administrative tenure award granted under company policy recognizing 10 consecutive years of service. Not an open-market discretionary trade.
Comprehensive Analysis
Executive Summary
On September 22, 2026, Alnylam Pharmaceuticals, Inc. ($ALNY) filed a Form 4 detailing an equity transaction by Chief Executive Officer and Director Yvonne Greenstreet. On September 19, 2026, Dr. Greenstreet acquired 107 shares of common stock at $0.00 per share.
Transaction Details
- Transaction Code:
A(Grant, award, or other acquisition pursuant to an employee benefit plan). - Nature of Acquisition: The shares were granted pursuant to an issuer policy originally approved on February 23, 2016, which awards common stock valued at $50,000 gross to employees who achieve 10 consecutive years of service. The 107 shares represent the net distribution after minimum statutory tax withholding.
- Holdings Post-Transaction: Following this issuance, Dr. Greenstreet directly owns 95,802 shares of ALNY common stock, in addition to 407 shares held indirectly through a managed 401(k) account.
Market and Sentiment Impact
- Significance: Low.
- Assessment: This filing reflects an automatic, corporate-wide policy award for a 10-year employment milestone rather than an open-market insider purchase or strategic compensation decision. As a result, the transaction has negligible direct signaling value regarding operational performance or insider sentiment on valuation.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.